ENGEN BIO

Engen Bio

Pharmaceuticals, 61 Avondale Ave, REDWOOD CITY, California, 94062, United States, 1-10 Employees

engenbio.com

  • LinkedIn

Who is ENGEN BIO

EnGen is an early-stage biotechnology company pioneering a new approach to preventing and treating influenza. We're developing an effective, easy-to-manufacture, shelf-stable universal fl...

Read More

map
  • 61 Avondale Ave, REDWOOD CITY, California, 94062, United States Headquarters: 61 Avondale Ave, REDWOOD CITY, California, 94062, United States
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: Under $1 Million

industries-icon Industry: Pharmaceuticals

SIC SIC Code: 2836

checked-icon Does something look wrong? Fix it. | View contact records from ENGEN BIO

ENGEN BIO Org Chart and Mapping

Employees

Mark Baer

Vice President, Research

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding ENGEN BIO

Answer: ENGEN BIO's headquarters are located at 61 Avondale Ave, REDWOOD CITY, California, 94062, United States

Answer: ENGEN BIO's official website is https://engenbio.com

Answer: ENGEN BIO's revenue is Under $1 Million

Answer: ENGEN BIO's SIC: 2836

Answer: ENGEN BIO has 1-10 employees

Answer: ENGEN BIO is in Pharmaceuticals

Answer: ENGEN BIO contact info: Phone number: Website: https://engenbio.com

Answer: EnGen is an early-stage biotechnology company pioneering a new approach to preventing and treating influenza. We're developing an effective, easy-to-manufacture, shelf-stable universal flu vaccine that confers long-term immunity to all Type A influenza strainsincluding those which cause seasonal flu and influenza pandemics. Seasonal flu causes 250,000 to 500,000 deaths every year. The CDC and other experts have cautioned that we are extremely vulnerable to the catastrophic occurrence of a global flu pandemicon a scale that could far exceed both COVID-19 and the Spanish flu of 1918. In its Global Influenza Strategy (20192030) report, the World Health Organization has declared the development of a universal flu vaccine as an urgent needbut the unique nature and genetic makeup of the influenza virus poses a challenge to researchers focused on influenza treatment and vaccination. To address these issues, EnGen Bio is developing universal vaccines for Type A flu prevention. Effective for vaccination in both the $6B human and $0.5B veterinary markets, our antibodies also demonstrate potential for therapeutic treatment of influenza, with an additional $2B prospective market. If successful, our efforts will eradicate flu pandemics and dramatically decrease the global burden of illness and disease caused by influenza.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access